September 28, 2020

The Niche

Knoepfler lab stem cell blog

IPSC RPE

1 min read

Some good news today as the pioneering induced pluripotent stem (IPS) cell trial led by Dr. Masayo Takahashi will resume. This clinical study with a focus on macular degeneration has been on hold for quite some time due to regulatory changes in Japan. There had also been concerns over mutations in the 2nd patient’s IPS cell product. As previous signs had indicated, the new clinical work will have an allogeneic focus, most likely drawing IPS cells from a bank. According to a Japan Times …Read More

3 min read

Can cells produced from autologous induced pluripotent stem cell (IPSC or IPS cell) cultures sometimes be immunogenic in patients? This key question has remained somewhat unsettled due to varied findings over the years (e.g. see here), but many of us had generally felt in the last couple years that IPS cell derivative immunogenicity in an autologous context wouldn’t be a major problem. This is a big deal because if human IPS cell cultures and in particular their derivatives are immunogenic (sparking a major immune …Read More

2 min read

The pioneering induced pluripotent stem cell (IPSC) clinical study in Japan led by top stem cell clinical researcher Dr. Masayo Takahashi has been stopped reports the WSJ in Japan. This development is confirmed by other sources and in a PDF report by RIKEN (in Japanese here). One patient was transplanted in September 2014 with their own IPSC-derived retinal pigment epithelial cells (using an innovative RPE sheet, see image) for treatment of macular degeneration. The study then moved on to a possible second patient, whose IPSC did …Read More